We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The DIET Trial - Dietetic Intervention in Psoriatic Arthritis (DIET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03142503
Recruitment Status : Completed
First Posted : May 5, 2017
Last Update Posted : May 5, 2017
Information provided by (Responsible Party):
Marcelo M Pinheiro, Federal University of São Paulo

Brief Summary:
Psoriasis (Ps) and psoriatic arthritis (PsA) are associated with increased risk of metabolic syndrome (MetS), body fatness and cardiovascular risk. Additionally, oxidative stress and inflammation are also contributing mechanisms on Ps and PsA. However, little is known about the influence of diet and micronutrients on the main outcomes of these diseases. The aim of the investigators is to evaluate the effectiveness of an intervention diet program on disease activity, metabolic profile and oxidative stress inpatients with Psoriasis and Psoriatic Arthritis.

Condition or disease Intervention/treatment Phase
Arthritis, Psoriatic Metabolic Syndrome Dietary Supplement: Diet + supplementation Dietary Supplement: Diet + placebo Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 194 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Effectiveness of a Dietary Intervention Program on Disease Activity, Metabolism and Oxidative Stress in Patients With Psoriatic Arthritis and Psoriasis Activity: A Clinical, Randomized, Placebo-controlled Trial
Actual Study Start Date : January 21, 2013
Actual Primary Completion Date : March 16, 2015
Actual Study Completion Date : June 22, 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Soybean supplementation
Dietary Supplement: Placebo
Supplementation of 1g soybean oil, 3 times a day.

Active Comparator: Diet + placebo
Soybean supplementation and diet intervention
Dietary Supplement: Diet + placebo
Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.

Experimental: Diet + Supplementation
Omega 3 and diet intervention
Dietary Supplement: Diet + supplementation
Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.

Primary Outcome Measures :
  1. Disease activity [ Time Frame: 12 weeks ]
    To evaluate the increase of Minimal Disease Activity (MDA) after intervention

Secondary Outcome Measures :
  1. Fat Mass [ Time Frame: 12 weeks ]
    To analyze the decrease of Fat Mass Index (kg/m^2)

  2. Lean Mass [ Time Frame: 12 weeks ]
    To evaluate the increase of Muscle Mass (kg)

  3. Waist circumference [ Time Frame: 12 weeks ]
    To observe the improvement of waist circumference (cm)

  4. Body Mass Index [ Time Frame: 12 weeks ]
    To analyze the improvement of Body Mass Index (kg/m^2)

  5. Glycation markers [ Time Frame: 12 weeks ]
    To analyze the decrease of receptor for advanced glycation end products receptor (RAGE)

  6. Anti-inflammatory marker [ Time Frame: 12 weeks ]
    To analyze the increase of adiponectin

  7. Lipidic Peroxidation [ Time Frame: 12 weeks ]
    To analyze the improvement of malondialdehyde (TBARs)

  8. Inflammatory markers [ Time Frame: 12 weeks ]
    To observe the improvement of LDL fractions

  9. Cutaneous activity [ Time Frame: 12 weeks ]
    To evaluated the reduction in cutaneous activity, evaluated by PASI (Psoriasis Area Severity Index)

  10. Articular activity [ Time Frame: 12 weeks ]
    To evaluate the decrease of articular activity, evaluated by DAS28-CRP (Disease Activity Score-C reactive protein) and DAS28-ESR (Disease Activity Score-Erythrocyte Sedimentation Rate).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with psoriatic arthritis, according to the Classification Criteria of Psoriatic Arthritis (CASPAR)

Exclusion Criteria:

  • lack of written informed consent;
  • age < 18 years old;
  • history of gastrointestinal, endocrine, pulmonary, kidney, hepatic, and neuromuscular diseases, as well as HIV-positive;
  • pregnant or breast-feeding women;
  • previous history of cancer;
  • use of steroids, protein supplements, vitamins, multivitamins, or antioxidants.
  • Specific medications to PsA and physical activity were required to be stable for the last 3 months to be included in the study
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Marcelo M Pinheiro, Assistant Professor, Federal University of São Paulo
ClinicalTrials.gov Identifier: NCT03142503    
Other Study ID Numbers: 2012/18701-2
First Posted: May 5, 2017    Key Record Dates
Last Update Posted: May 5, 2017
Last Verified: May 2017
Keywords provided by Marcelo M Pinheiro, Federal University of São Paulo:
psoriatic arthritis
body composition
DXA measurements
diet therapy
adipose tissue
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Psoriatic
Metabolic Syndrome
Joint Diseases
Musculoskeletal Diseases
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases